1. Genentech wants to double its San Francisco footprint — Biotechs with the biggest cash piles — Purdue Pharma wants to pay bonuses even under bankruptcy proceedings — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Closing date pushed back to 2020?

Discussion in 'Celgene' started by anonymous, Jun 24, 2019 at 8:12 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This is the thin end of the wedge. Wouldn't be surprised if BMS throw in the towel.
     
  2. anonymous

    anonymous Guest

    I would agree with you. Not surprised at all if this happens. What are the financial penalties that would have to be paid if the deal is backed out?
     
  3. anonymous

    anonymous Guest

    $2 billion. But BMS stock would crumble - Giovanni would be removed and BMS would be bought out for cheap.

    Ain’t gunna happen. The Celgene deal is what BMS needs. They don’t care about I&I and have discounted ozanimod impact bc the drug is a dog. They will do anything to make this deal close.
     
  4. anonymous

    anonymous Guest

    Agree with most points but not ozanimod opinion. If it was indeed a “dog” BMS would not have included it as part of the CVR agreement and requirements.
     
  5. anonymous

    anonymous Guest


    The fact that it's in the CVR says how little they think of it. Me thinks you don't understand the CVR route.
     
  6. anonymous

    anonymous Guest

    Exactly! CVR terms = they don’t think it will ever happen (or not on the dates they’ve agreed). I will be selling those fucking things the second they’re issued even if it’s for $0.50
     
  7. anonymous

    anonymous Guest

    So if they don’t think the CVR products will happen then why is BMS interested in buying Celgene at all? It’s certainly not for Revlimid or Abraxane. It’s for near future products which have blockbuster potential which mostly includes those in the CVR agreement.
     
  8. anonymous

    anonymous Guest


    of course they want the products in the CVR to do well but they handicapped them by putting them in the CVR to pay less for Celgene. Alles could have had a cash/stock deal for $106 yet he bungled it to 50+stock+cvr! The winner = BMY. Damn you are simple. It's all there in the 10ks from both companies. Go read them.
     
  9. anonymous

    anonymous Guest

    you are expecting way to much from the simple minds of pharma reps and managers.
     
  10. anonymous

    anonymous Guest

    BMY is the winner. Alles got terribly desperate as time went on and stock was deteriorating quickly $50 + stock + CVR was all he could get at that point. Cafario desperately wants and needs the pipeline so CVR is important. Alles was eager to reach a selling agreement but also knew what he had in the pipeline. Don’t get the 10k comment.
     
  11. anonymous

    anonymous Guest

    I'm telling ya it's the gays and fhags. Once the signage and flags changed to show off the swordfighters and fudgepackers shit went downhill.
     
  12. anonymous

    anonymous Guest

    well, the good news is lots of companies want Otezla. Bad news, no one can afford our blockbuster. Now what??
     
  13. anonymous

    anonymous Guest

    I was glad to see HR is giving us the same generous severance package that was originally announced with BMS.

    Now it’s just a waiting game...
     
  14. anonymous

    anonymous Guest

    How many will actually ever get the supposed severance package? Don’t trust them.
     
  15. anonymous

    anonymous Guest

    Exactly, I wonder how messy this will get. You may have to get a lawyer to make sure they comply
     
  16. anonymous

    anonymous Guest

    if the divestiture happens before the deal closes I believe the change in control states we are legally considered to be terminated without cause and we will get our payouts. Then it’s a double dip for whoever buys otezla if they want to keep us carrying the bag and recruit us as employees.

    I hope that’s the case. Need to have my employment lawyer father in law review all these documents this weekend
     
  17. anonymous

    anonymous Guest


    Nope, that’s not true. Did you not listen to the town hall, read the faqs or have common sense? If otezla is sold, no matter when-before or after the bms-celg deal, and the buying company retains you- no severance. You will only get severance if the buying company doesn’t keep you or if they offer you a job that isn’t within reason-like you would have to move or a change in your territory etc. in that case you have good cause to decline the offer and get severance.
     
  18. anonymous

    anonymous Guest

    You’re an idiot. Re-read the FAQs you clown. Divestiture = severance
     
  19. anonymous

    anonymous Guest

    All I’m sure about is either way we now get vested in our stock.
    Only get severance if new company does NOT keep us.
    It’s the focus bonus I’m not 100% on.....? If we close before the merger we may not get it- I think ??